Lenvatinib, Free Base

Lenvatinib, Free Base
Item number Size Datasheet Manual SDS Delivery time Quantity Price
LC-L-5400_25mg 25 mg -

3 - 15 business days*

83.00€
LC-L-5400_50mg 50 mg -

3 - 15 business days*

105.00€
LC-L-5400_100mg 100 mg -

3 - 15 business days*

126.00€
LC-L-5400_200mg 200 mg -

3 - 15 business days*

158.00€
LC-L-5400_250mg 250 mg -

3 - 15 business days*

184.00€
LC-L-5400_500mg 500 mg -

3 - 15 business days*

285.00€
LC-L-5400_1g 1 g -

3 - 15 business days*

426.00€
LC-L-5400_2g 2 g -

3 - 15 business days*

713.00€
LC-L-5400_5g 5 g -

3 - 15 business days*

1,587.00€
 
Soluble in DMSO. Lenvatinib, also known as E7080, is an active inhibitor of multiple receptor... more
Product information "Lenvatinib, Free Base"
Soluble in DMSO. Lenvatinib, also known as E7080, is an active inhibitor of multiple receptor tyrosine kinases, with IC50 values of 22 nM (VEGFR1), 4 nM (VEGFR2), 5.2 nM (VEGFR3), 46 nM (FGFR1), 51 nM (PDGFRa), 39 nM (PDGFRb), and 100 nM (KIT). It inhibited SCF- and VEGF-induced angiogenesis of human umbilical vein endothelial cells that express the SCF receptor KIT, with IC50 values of 5.2 nM and 5.1 nM, respectively. Lenvatinib inhibited tumor growth in the human small cell lung cancer H146 xenograft model. Matsui J., et al. 'E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition.' Int. J. Cancer 122: 664-671 (2008). This research compound is the free base form of lenvatinib. We also plan to offer the methanesulfonate salt form, please see Cat. No. L-5433, Lenvatinib, Methanesulfonate Salt. The methanesulfonate salt form will be added to our website as soon as the first lot is ready for shipment. The maximum tolerated dose (MTD) for lenvatinib with carboplatin/paclitaxel is 4?mg BID in advanced non-small cell lung cancer patients. Lenvatinib at the MTD demonstrated tolerability and encouraging antitumor activity. Nishio M., et al. 'Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer.' Br. J. Cancer 109: 538-544 (2013). Lenvatinib had manageable toxicity and showed preliminary activity for durable disease control. The antiangiogenic activity of lenvatinib might be correlated with its antitumor activity in patients with a wide range of solid tumors. Yamada K., et al. 'Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors.' Clin. Cancer Res. 17: 2528-2537 (2011).
Keywords: E7080, ER20349200
Supplier: LC Laboratories
Supplier-Nr: L-5400

Properties

Application: Antineoplastic, Receptor tyrosine kinase inhibitor
MW: 426.85 D
Formula: C21H19ClN4O4
Purity: >99%
Format: Solid

Database Information

CAS : 417716-92-8| Matching products
KEGG ID : K05096 | Matching products

Handling & Safety

Storage: -20°C
Shipping: +20°C (International: +20°C)
Signal Word: Warning
GHS Hazard Pictograms:
H Phrases: H302+H312+H332
P Phrases: P262
Caution
Our products are for laboratory research use only: Not for administration to humans!
You will get a certificate here
or to request a certificate of analysis.
Read, write and discuss reviews... more
Customer review for "Lenvatinib, Free Base"
Write a review
or to review a product.
Viewed